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Role of Protein Tyrosine Phosphatases in Regulating the Immune
System: Implications for Chronic Intestinal Inﬂammation
Marianne R. Spalinger, MSc,* Declan F. McCole, PhD,† Gerhard Rogler, MD, PhD,*,‡
and Michael Scharl, MD*,‡
Abstract: Current hypothesis suggests that genetic, immunological, and bacterial factors contribute essentially to the pathogenesis of inﬂammatory
bowel disease. Variations within the gene loci encoding protein tyrosine phosphatases (PTPs) have been associated with the onset of inﬂammatory bowel
disease. PTPs modulate the activity of their substrates by dephosphorylation of tyrosine residues and are critical for the regulation of fundamental cellular
signaling processes. Evidence emerges that expression levels of PTPN2, PTPN11, and PTPN22 are altered in actively inﬂamed intestinal tissue. PTPN2
seems to be critical for protecting intestinal epithelial barrier function, regulating innate and adaptive immune responses and ﬁnally for maintaining
intestinal homeostasis. These observations have been conﬁrmed in PTPN2 knockout mice in vivo. Those animals are clearly more susceptible to
intestinal and systemic inﬂammation and feature alterations in innate and adaptive immune responses. PTPN22 controls inﬂammatory signaling in
lymphocytes and mononuclear cells resulting in aberrant cytokine secretion pattern and autophagosome formation. PTPN22 deﬁciency in vivo results in
more severe colitis demonstrating the relevance of PTPN22 for intestinal homeostasis in vivo. Of note, loss of PTPN22 promotes mitogen-activated
protein kinase–induced cytokine secretion but limits secretion of nuclear factor kB–associated cytokines and autophagy in mononuclear cells. Loss of
PTPN11 is also associated with increased colitis severity in vivo. In summary, dysfunction of those PTPs results in aberrant and uncontrolled immune
responses that result in chronic inﬂammatory conditions. This way, it becomes more and more evident that dysfunction of PTPs displays an important
factor in the pathogenesis of chronic intestinal inﬂammation, in particular inﬂammatory bowel disease.
(Inﬂamm Bowel Dis 2015;21:645–655)
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C urrent hypothesis suggests that genetic, immunological, andbacterial factors contribute essentially to the pathogenesis of
inﬂammatory bowel disease (IBD). An epithelial barrier defect,
coupled with a dysfunctional immune response of the innate and
the acquired immune system to commensal ﬂora results in either
excessive upregulation or impaired downregulation of inﬂammatory
events, what ﬁnally drives the development of chronic intestinal
inﬂammation.1 The predispositions are genetically determined, and
genome-wide association studies (GWAS) identiﬁed variations in
about 160 gene loci being associated with IBD.2 Many of the
identiﬁed risk genes are critically involved in bacterial recognition,
induction of antimicrobial factors, activation and modulation of
innate and adaptive immune responses, and the maintenance of
intestinal epithelial barrier function.
Phosphorylation and dephosphorylation of speciﬁc amino
acid residues, in particular tyrosine residues, represent a funda-
mental mechanism for the activation and inactivation of intracel-
lular signaling molecules. Dephosphorylation is performed by
a large number of different protein phosphatases. One important
family of such proteins is protein tyrosine phosphatases (PTPs).
Members of this family play an essential role in the regulation of
critical cell signaling events, i.e., proliferation, differentiation, and
cell survival. Recent studies demonstrated a pivotal role for PTPs
in the regulation of inﬂammatory and antibacterial responses.3
In this review, we will summarize the most recent
knowledge about the role of PTPNs in the pathogenesis of
chronic intestinal inﬂammation, in particular IBD.
PTP NON-RECEPTOR TYPE 22
In the past decade, GWAS revealed a strong association
between 2 different single nucleotide polymorphisms (SNPs) in
the gene locus encoding protein tyrosine phosphatase non-
receptor type 22 (PTPN22) and several inﬂammatory disorders,
including the IBD subforms, Crohn’s disease (CD)2,4 and ulcera-
tive colitis (UC),2,4 systemic lupus erythematodes,5 rheumatoid
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arthritis,6,7 type 1 diabetes (T1D),8 and others.9 One disease-
associated SNP (C1858.T; SNP ID: rs2476601) results in the
substitution of Arginine 620 with a tryptophan residue in the
protein product (referred to as 620W variant), whereas in the other
SNP (G788.C; SNP ID: rs33996649), arginine 263 is substituted
with a glutamine residue (referred to as 263Q variant).
Arginine 263 lies within the catalytic domain of the protein,
and substitution with a glutamine residue results in decreased
phosphatase activity.10 Of note, presence of the 263Q variant
reduces the risk to develop systemic lupus erythematodes and
rheumatoid arthritis10,11 and protects from UC onset.4 PTPN22
620W in contrast is associated with increased risk for developing
rheumatoid arthritis,6,7 systemic lupus erythematodes,5 and T1D8
but reduces the risk to develop CD.4 Initial studies by Vang et al12
demonstrated that presence of this genetic variation results in
a gain-of-function PTPN22 variant causing inhibition of the T-cell
receptor signaling cascade. Furthermore, this variant features
increased in vitro dephosphorylation capacity,12 possibly resulting
from reduced PTPN22 phosphorylation at an inhibitory
residue.13,14 In contrast, one study using mice that express the
disease-associated PTPN22 variant, suggested that the PTPN22
619W variant (the murine ortholog of human PTPN22 620W)
results in reduced protein stability and therefore in a loss-of-
function effect of this variant.15 However, this ﬁnding could not
be conﬁrmed in other studies using an independently generated
PTPN22 619W knockin strain.16
In vivo silencing of PTPN22 by siRNA interference caused
phenotypically opposite effects on B-cell differentiation when
compared with the effects of the presence of the PTPN22 620W
allele in humans.17 This further supports the gain-of-function
hypothesis. Wang et al18 recently proposed that the 620W variant
might be an altered function, rather than a loss- or gain-of-
function variant, proposing altered substrate speciﬁcity of the
variant as possible mechanism for the observed effects.18 Never-
theless, in general, the PTPN22 620W variant is nowadays re-
garded as a gain-of-function variant.
PTPN22 in Lymphocytes
PTPN22 is expressed in both, myeloid and lymphoid
immune cells, but barely present in nonhematopoietic cell types.19
Given the strong association with inﬂammatory diseases, several
studies addressed the role of PTPN22 in immune cell signaling. In
T cells, PTPN22 activity attenuates T-cell antigen receptor (TCR)
signaling by interacting with and dephosphorylating the TCR-
associated kinases lymphocyte-speciﬁc protein tyrosine kinase
(Lck) and zeta-chain associated protein (ZAP)-70.20,21 Presence
of the gain-of-function variant results in reduced T-cell receptor
signaling in T1D patients and healthy individuals,14 whereas
PTPN22-deﬁcient T cells are hyperresponsive to TCR ligation.22
PTPN22-deﬁcient mice, in contrast, display increased levels of
effector and memory T cells but interestingly do not show signs
of autoimmunity.22 This observation was explained in additional
studies, which revealed that PTPN22-deﬁcient regulatory T cells
show enhanced suppressor functions and thereby are able to
counteract the increased T cell activation found in PTPN22-
deﬁcient effector T cells.23
Presence of the PTPN22 620W variant leads to an increased
frequency of autoreactive B-cell clones in healthy individuals24,25
and T1D patients.25 Several studies argue that this is the result of
B-cell intrinsic defects,16 such as enhanced survival of autoreac-
tive B cells at the transition from immature to naive B cells24,25
due to changed breakpoint cluster region signaling.24,25 A more
recent study however claims that this effect might result from
changes in follicular Th-cell activation, which drives altered acti-
vation of B cells in germinal centers, rather than from a B-cell
intrinsic effect.26
PTPN22 in Myeloid Immune Cells
Most studies addressing PTPN22 function have been
performed in lymphocytes, but PTPN22 expression is very high
in other immune cell types as well, including neutrophils, macro-
phages, and dendritic cells.15,19 We showed that loss of PTPN22 in
monocytes results in profound changes in interferon gamma (IFN-
g)-induced signaling with reduced signal transducer and activator
of transcription (STAT) 1, but strongly enhanced p38 mitogen-
activated protein kinase (MAPK) activation, ultimately resulting
in drastically enhanced interleukin (IL)-6 secretion together with
reduced IL-12 levels.27 Furthermore, loss of PTPN22 also resulted
in an altered response to the bacterial wall product, muramyl dipep-
tide (MDP), with enhanced autophagy induction but also increased
secretion of proinﬂammatory IL-6 and IL-827; hence, loss of
PTPN22 in myeloid immune cells results in an increase in the
secretion of proinﬂammatory cytokines (Fig. 1).
Wang et al18 demonstrated that presence of the PTPN22
620W variant results in impaired type-1 IFN production on TLR4
ligation, and loss of PTPN22, or the presence of the 620W variant,
promotes differentiation of monocytes into proinﬂammatory M1
FIGURE 1. PTPN22 controls IFN-g- and MDP-induced signaling cas-
cades. Loss of PTPN22 promotes p38 MAPK and canonical NFkB
activation and increases MDP-induced autophagy. However, loss of
PTPN22 results in decreased STAT activity. Taken together, this results
in a highly imbalanced cytokine secretion pattern. ICAM-1, intercellular
adhesion molecule 1; IFN, interferon; IFNR, interferon receptor; MCP-1,
monocyte chemoattractant protein 1; NFkB, nuclear factor kB; NOD2,
nucleotide oligomerization containing protein 2.
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macrophages.28 Dendritic cells from PTPN22-deﬁcient mice ex-
pressed higher levels of the costimulatory molecule CD40 and
induced higher proliferation of OT-II T cells in in vitro coculture
experiments.15
PTPN22 in Patients with IBD
The PTPN22 gain-of-function variant is regarded as
a general autoimmune risk allele, as it is associated with increased
risk to develop several autoimmune disorders.9 Interestingly, the
gain-of-function variant at the same time results in a reduced risk
to develop CD.4 This opposite effect on intestinal inﬂammation
evokes the question about the underlying mechanism(s). We
found that PTPN22 expression is reduced in patients with both
UC and CD, with a dominant downregulation in CD68+ mono-
nuclear cells. However, only a slight difference in PTPN22
expression in T or B cells was observed,27 indicating an important
role of PTPN22 in the myeloid cell compartment for maintaining
intestinal homeostasis (Fig. 2).
PTPN22 in Experimental Colitis
Although several association studies revealed a relation
between PTPN22 and IBD susceptibility,4,29 only a few studies
addressed its functional role during intestinal inﬂammation. One
study showed that in a T-cell mediated colitis model, where naive
T cells were transferred into immune-deﬁcient mice, naive
PTPN22-deﬁcient T cells aggravated intestinal inﬂammation and
tissue damage.23 Interestingly, the transfer of PTPN22-deﬁcient
regulatory T cells—but not the transfer of wild-type regulatory T
cells—rescued this phenotype.23 This effect is attributed to
increased suppressive competence of PTPN22-deﬁcient regulatory
T cells.23 A recent study further revealed that PTPN22-deﬁcient
naive T cells proliferate faster, acquire full effector functions, and
loose self-tolerance in immune deﬁcient hosts.30 This might
explain how PTPN22-deﬁcient T cells are able to mediate
increased inﬂammation when injected into lymphopenic mice.
The important protective role of PTPN22 during intestinal
inﬂammation has further been conﬁrmed in 2 independent
studies using a dextran-sodium sulfate (DSS)-induced model
of acute colitis. In both studies, loss of PTPN22 resulted in
increased reaction to DSS with aggravated weight loss and
enhanced colitis severity.18,28 Enhanced colitis susceptibility has
been attributed to altered TLR4 signaling and type I interferon
production in one study,18 or altered macrophage polarization in
the other report,28 although the cell-type speciﬁc contribution
to intestinal inﬂammation has not been addressed directly. We
further observed that PTPN22 deﬁciency results in reduced mye-
lin peroxidase activation and decreased granulocyte inﬁltration
into the inﬂamed colon during DSS colitis (Spalinger MR, et al,
unpublished data, 2014), suggesting a role for PTPN22 in medi-
ating granulocyte function/recruitment.
As PTPN22 expression is reduced mainly in myeloid cells
within the intestine of patients with IBD,27 transfer of PTPN22-
deﬁcient T cells, or colitis induction in a setting where PTPN22 is
missing in all cells, might however be an incomplete approach to
address PTPN22 function during intestinal inﬂammation. Addi-
tional in vivo studies including PTPN22 deﬁciency speciﬁcally in
nonlymphoid immune cells would greatly improve our general
understanding on the role of PTPN22 in IBD.
In summary, patients with IBD feature have decreased
levels of PTPN22 in myeloid cells in the intestine. Several studies
demonstrated, that loss of PTPN22 in myeloid cells changes the
response toward proinﬂammatory cytokines and bacterial prod-
ucts. Hence, reduction of PTPN22, as observed in patients with
IBD importantly affects the cytokine balance within the inﬂamed
intestine, ultimately promoting disease persistence and progres-
sion (Fig. 3).
FIGURE 2. Reduced PTPN22 expression in patients with IBD. In the healthy intestine, high levels of IL-10 and TGF-b result in high expression of
PTPN22 in all immune cells. On epithelial damage, the proinﬂammatory cytokine milieu results in reduced PTPN22 expression speciﬁcally in cells
of the myeloid linage, whereas lymphoid cells still express high amounts of PTPN22. B, B cell; DC, dendritic cell; IFN, interferon; M/MF, macrophage;
M1, inﬂammatory macrophage; T, T cell.
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Protein Tyrosine Phosphatase Non-receptor
Type 2
The protein tyrosine phosphatase non-receptor type 2
(PTPN2) gene encodes the tyrosine phosphatase PTPN2, also
known as T-cell protein tyrosine phosphatase. PTPN2 was named
due to being originally cloned from a T-cell cDNA library.
However, it is ubiquitously expressed.31,32 In humans there are 2
functional variants of the PTPN2 enzyme that occur through alter-
native PTPN2 splicing. The larger 48 kD form is restricted to the
endoplasmic reticulum by a hydrophobic C-terminus that masks
a nuclear localization sequence. The more enzymatically active
45 kD variant lacks the hydrophobic C-terminus and can therefore
transit to the nucleus through the nuclear localization sequence
and is thus regarded as the mobile form of PTPN2.33,34 Indeed, in
response to an appropriate stimulus the 45 kD form can also exit
the nucleus and dephosphorylate target substrates in the cyto-
plasm and at the plasma membrane.35 PTPN2 is capable of de-
phosphorylating many protein tyrosine kinases such as the insulin
receptor, epidermal growth factor receptor (EGFR), Src family
kinases as well as several janus kinase (JAK) and STAT family
members.35–41 The PTPN2 gene has emerged as a site of distinct
clinical signiﬁcance due to the association of a number of SNPs in
the PTPN2 locus 18p11 with chronic inﬂammatory conditions
such as CD, UC, T1D, and celiac disease.42–44 The rs2542151
SNP has been the most widely identiﬁed PTPN2 SNP associated
with IBD. It was ﬁrst reported in the deﬁning Welcome Trust
Case Control Consortium article published in 2007 demonstrating
a link with CD.45 Follow-up studies conﬁrmed this association
and also identiﬁed links between the rs2542151 SNP with CD
and UC.43,46–50 Additional SNPs in the PTPN2 gene locus have
also been associated with IBD and disease outcomes. This in-
cludes the rs7234029 SNP that has a potential association with
a stricturing disease phenotype in CD subjects and may be linked
to early onset CD and UC.51 The rs1893217 SNP was originally
associated with T1D; however, it has emerged as a candidate SNP
in both adult and early-onset pediatric CD and UC, although
the effect of this SNP on the PTPN2 gene and function remains
to be determined.42,43,52 Nevertheless, the ﬁrst study points toward
the presence of a loss-of-function PTPN2 protein in variant
carrying cells.53
PTPN2 and Barrier Function Regulation
With respect to PTPN2 expression in IBD, colonic PTPN2
mRNA and protein expression is increased in active CD with
expression being most prominent in the epithelium.54,55 These
ﬁndings were supported by another study that also showed
increased PTPN2 protein expression in intestinal tissues (colon
and ileum) from patients with active CD.56 Consistent with this,
we have shown that in intestinal epithelial cell (IEC) lines, the
IBD-associated inﬂammatory cytokines, IFN-g, and tumor necro-
sis factor (TNF) are capable of increasing expression of
PTPN2.54,55 This suggests that these inﬂammatory cytokines
induce expression of a negative regulator of their own signaling
in an apparent negative feedback loop. Although expression of
PTPN2 is increased in CD, the impact of noncoding SNPs seems
to manifest in a loss of enzymatic activity or efﬁcacy, although the
full impact of individual SNPs on PTPN2 expression and function
has yet to be fully determined. A loss of PTPN2 expression has
been shown to have dramatic consequences for IECs and their
ability to form an effective barrier. siRNA knockdown of PTPN2
resulted in accentuated barrier defects induced by IFN-g treatment
of IEC.54 This included a greater decrease in transepithelial elec-
trical resistance in response to IFN-g coupled with a pronounced
increase in expression of the cation-selective pore-forming mole-
cule, claudin-2.54 Claudin-2 expression is elevated in colonic tis-
sues in patients with IBD, especially UC, and functionally, this
could contribute to symptoms of disease by permitting increased
paracellular passage of sodium ions into the intestinal lumen
FIGURE 3. Proposed mechanism, how PTPN22 is involved in IBD pathogenesis. Inﬂammatory insults result in high levels of TNF, IFN-g and IL-1b.
TNF and IL-1b reduce PTPN22 expression in myeloid immune cells. On loss of PTPN22, monocytes/macrophages secrete increased levels of IL-6
and IL-8 and differentiate preferentially into proinﬂammatory M1 macrophages. The increased expression of costimulatory molecules on DC
results in an enhanced activation of the adaptive immune system. B, B cell; DC, dendritic cell; IFN, interferon; M/MF, macrophage; M1, inﬂam-
matory macrophage; T, T cell.
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thus tangibly contribute to intestinal ﬂuid loss associated with
IBD.57–59 In addition to a further decrease in transepithelial elec-
trical resistance, PTPN2-deﬁcient cells also displayed increased
macromolecule permeability following IFN-g treatment as deter-
mined by increased apical–basolateral passage of FITC-dextran
across polarized IEC monolayers.54 Due to the width of the pore
size generated by claudin-2 being insufﬁcient to permit passage of
FITC-dextran (10 kD), this strongly suggests that additional
mechanisms capable of modifying tight junction components
responsible for regulation of macromolecule permeability are re-
cruited by IFN-g in cells lacking PTPN2.60 Conclusive evidence
of this has not yet been determined as PTPN2 knockdown that did
not cause further decreases in expression of the tight junction
proteins occludin or zonula occludens-1 by IFN-g, whereas a pos-
sible inﬂuence of PTPN2 on relocalization of tight junction pro-
teins has not been investigated.54 These data suggest that PTPN2
plays an important role in protecting intestinal epithelial barrier
function. A protective role for PTPN2 in intestinal barrier function
has also been indicated in vivo. Ptpn2 knockout mice exhibit
a pronounced phenotype at 3 to 5 weeks of age that is character-
ized by systemic inﬂammation, hematopoietic defects, increased
levels of proinﬂammatory cytokines, splenomegaly, and diarrhea.
The severity and kinetics of the inﬂammation in mice are strain
dependent with an accelerated morbidity for mice on a Balb/c
background compared with mice on a C57BL/6 background.61,62
Bone marrow chimeric studies indicated that the inﬂammation
and mortality in mice on the Balb/c background were governed
by loss of Ptpn2 in the nonhematopoietic compartment.63 Studies
with heterozygous Ptpn2-deﬁcient mice showed that these mice
have no overt inﬂammatory phenotype and exhibit normal sur-
vival rates. However, they did exhibit increased sensitivity to
DSS-induced colitis suggesting that Ptpn2/PTPN2 deﬁciency in-
creases the susceptibility of the intestine to agents that disrupt the
epithelial barrier.64
One additional area of epithelial function that can contrib-
ute to the broader concept of “barrier function” is appropriate
regulation of electrolyte transport. This is essential for absorption
and secretion of electrolytes and ﬂuids as well as being responsi-
ble for the absorption of nutrients, maintenance of luminal pH,
and preserving the sterility of intestinal crypts.65 Epithelial elec-
trolyte transport is suppressed in IBD, and this is believed to con-
tribute to overall ﬂuid loss through decreased absorptive capacity,
as well as creating an environment conducive to increased bacterial
interactions with the intestinal epithelium.66–68 PTPN2 has been
shown to play a role in regulating ﬂuid secretion. Speciﬁcally,
PTPN2 knockdown in T84 colonic epithelial cells accentuated epi-
dermal growth factor inhibition of Ca2+-stimulated chloride secre-
tion thus promoting EGFR suppression of electrolyte secretion.69
Thus, it is possible that PTPN2 mutations resulting in a loss of
enzymatic activity could encourage elevated or prolonged EGFR
phosphorylation and exacerbate overall dysregulation of intestinal
ﬂuid homeostasis.
As discussed later in this article, loss of PTPN2 expression
also has consequences for other aspects of innate and adaptive
immunity including autophagy and T-cell function.53,70 Given that
PTPN2 represents a point of convergence for multiple aspects of
intestinal homeostasis, it may therefore play a key role in multiple
IBD-associated physiological events and thus, like other IBD
candidate genes, make a greater cumulative contribution to IBD
pathogenesis than suggested by the genetic prevalence of PTPN2
SNPs in sampled populations. Therefore, clinically relevant loss-
of-function mutations in the PTPN2 gene may contribute, at least
in part, to the development of IBD and other chronic inﬂamma-
tory intestinal diseases through a compromised epithelial barrier.
Indeed, given that increased intestinal permeability is a feature of
IBD, T1D, and celiac disease, this may be one avenue to explore
commonality in the etiology of these conditions arising from
PTPN2 mutations (Fig. 4).
PTPN2 and Innate Immune System
Studies with Ptpn22/2 mice conﬁrmed that PTPN2 is a key
negative regulator of cytokine signaling. These animals develop
progressive systemic inﬂammatory disease as demonstrated by
chronic myocarditis, gastritis, nephritis, and sialadenitis as well
as elevated serum levels of IFN-g, IL-12, TNF, and nitric oxide.
These cytokines seem to be mostly produced by mononuclear
cells. Interestingly, PTPN2-deﬁcient mice also present increased
sensitivity to the bacterial wall component, lipopolysaccharide,
in vivo and in vitro cultured macrophages from Ptpn22/2 mice
are hypersensitive to lipopolysaccharide.63
Recent data have demonstrated that PTPN2 regulates IFN-
g-induced signaling and effects in cell models of chronic intesti-
nal inﬂammation. Treatment of human IEC with IFN-g increases
PTPN2 mRNA and protein levels, elevates enzymatic PTPN2
activity, and causes cytoplasmic accumulation of PTPN2. Similar
as in ﬁbroblasts, these effects are mediated through the cellular
energy sensor, adenosine monophosphate–activated protein
FIGURE 4. PTPN2 functions in IEC. Loss of PTPN2 or presence of PTPN2
variants results in reduced barrier function, and suppression of elec-
trolyte secretion resulting in a disturbed liquid/electrolyte balance.
Furthermore, PTPN2 deﬁciency results in enhanced autophagy and
increased secretion of proinﬂammatory cytokines.
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kinase. Knockdown studies using PTPN2-speciﬁc siRNA con-
structs revealed that dephosphorylation of STAT1+3 is dependent
on PTPN2 in these cells.54
In PTPN2-deﬁcient human THP-1 monocytic cells IFNg
induced activity of the MAPK-subunit p38. Additionally, secre-
tion of monocyte chemoattractant protein 1 (MCP-1) and IL-6
were enhanced.71 PTPN2 also regulates signaling responses to
the bacterial wall component MDP in human monocytes ﬁnally
resulting in enhanced secretion of IFN-g but reduced secretion
of IL-8 and TNF from these cells. This might be due to the fact
that dysfunction of PTPN2 in human monocytes causes
enhanced MAPK signaling in response to MDP. Of note, PTPN2
dysfunction also resulted in enhanced cleavage of caspase-1 and
increased IL-1b secretion, indicative of increased inﬂammasome
activation, in response to MDP.53 Further studies demonstrated
that TNF induces PTPN2 protein and mRNA levels in human
IEC through a nuclear factor kB–dependent mechanism. PTPN2
in turn regulates TNF-induced ERK- and p38-MAPK activity as
well as IL-6 and IL-8 secretion.55 A further study also demon-
strated that PTPN2 controls TNF-induced IL-6 secretion in
mouse embryonic ﬁbroblasts.39 These ﬁndings strongly suggest
that PTPN2 is crucial for maintaining intestinal homeostasis and
controlling cytokine secretion from IECs, ﬁbroblasts, and mono-
nuclear cells.
PTPN2 Regulates Autophagosome Formation
Autophagy is a fundamental process for bulk degradation of
cytoplasmic compartments, damaged organelles and/or misfolded
proteins. In autophagosomes, these structures are sequestered into
double-membrane-enclosed vesicles and delivered to lysosomes
for ﬁnal degradation.72–74 Autophagy is activated by stress con-
ditions, such as starvation or hypoxia, and dysfunction of autoph-
agy has been implicated in numerous pathologies, such as cancer
or neurodegeneration.75 Autophagy is also critically involved in
host defense against intracellular pathogens, such as Listeria
monocytogenes or Salmonella typhimurium.76–78 This observation
further supports the hypothesis that abnormal immune responses
to luminal bacteria or bacterial antigens play an essential role for
the manifestation of CD. Previous data have well demonstrated
that presence of genetic variations within autophagy genes results
in a defective bacterial handling, prolonged intracellular survival
of pathogenic bacteria, and an uncontrolled inﬂammatory
situation.
Recent data demonstrated that PTPN2 not only regulates
the cytokine-induced activation and expression of autophagy-
related molecules but is also involved in the regulation of
autophagosome formation in IEC.79 siRNA-induced knockout of
PTPN2 in IEC inhibits the expression of several autophagy-
associated molecules, including beclin-1, ATG5, ATG7,
ATG12, ATG16L1, and IRGM in response to IFN-g and TNF
cotreatment. Of note, reduced protein levels of all of these
autophagy markers have also been observed in intestinal tissue
samples derived from patients with active CD when compared
with tissue samples from non-IBD controls.79
On a functional level, loss of PTPN2 in human IEC
completely abrogated the increase in LC3B-II protein levels and
the formation of LC3B-positive (LC3B+) subcellular structures in
the cells, indicating reduced autophagosome formation, in
response to TNF and IFN-g cotreatment. Furthermore, PTPN2-
deﬁcient cells feature only a small number of LC3B+ vesicles
overall and TNF and IFN-g cotreatment caused the formation of
fewer, but larger LC3B+ vacuoles that were localized close to cell
borders.79 The appearance of such abnormal large autophagic
vacuoles has been regarded as a marker of an ineffective
formation of dysfunctional autophagosomes due to a defective
autophagy process in these cells.80 Similar likely dysfunctional
autophagosomes were observed in PTPN2-deﬁcient MDP-
treated human monocytes.53 Interestingly, the effects of PTPN2
on autophagosome formation seemed to be mediated by control-
ling the phosphorylation status of the EGFR and subsequently of
phosphatidylinositol 3-kinase (PI3K), Akt, and molecular target
of rapamycine activity.79
Using primary colonic lamina propria ﬁbroblasts (CLPF)
isolated from patients with CD featuring either the PTPN2-WT or
the CD-associated PTPN2 variant, rs2542151, it was demon-
strated that presence of the disease-associated PTPN2 variant
exerts similar effects than siRNA-induced loss of PTPN2
expression.79 In particular, CLPFs featuring the CD-associated
PTPN2 variant revealed reduced basal levels of PTPN2 protein
when compared with PTPN2-WT ﬁbroblasts and the increase in
PTPN2 protein in response to TNF and IFN-g treatment was
absent in the variant cells. As in IEC, PTPN2 dysfunction also
prevented the cytokine-induced rise in the expression of autoph-
agy markers, such as IRGM and also resulted in diminished for-
mation of autophagosomes in PTPN2-variant carrying CLPF.79
Impaired autophagy has been described to result in
defective handling of invading bacteria and a defective handling
of luminal and/or invading bacteria might critically contribute to
the onset of IBD. Therefore, the question arises whether PTPN2
dysfunction might result in ineffective clearance of invading
bacteria due to the altered autophagosome formation. Interest-
ingly, using GFP-labeled L. monocytogenes, it has been demon-
strated that defective PTPN2 function results in enhanced levels
of intracellular L. monocytogenes and reduced numbers of auto-
phagosome as well as of LC3B-II protein levels in IEC. These
ﬁndings were fully conﬁrmed using CLPF from patients being
either PTPN2 wild type or variant.79 Presence of the CD-
associated PTPN2 variant in CLPF caused similar effects with
respect to autophagosome formation and the number of invading
bacteria as PTPN2 deﬁciency in IEC. In PTPN2-variant CLPF,
LC3B-staining was clearly less detectable while a strong GFP+
staining, suggestive for a large number of intracellular L. mono-
cytogenes, was observed.79 These data demonstrate that dysfunc-
tion of PTPN2 results in impaired autophagosome formation and
defective handling of invading bacteria and suggest how presence
of the CD-associated PTPN2 variant within intestinal cells could
critically contribute to the onset of IBD by causing a defective
function of the innate immune system.
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PTPN2 and Adaptive Immune System
PTPN2 had initially been termed as T-cell protein tyrosine
phosphatase, which indicates that it was ﬁrst detected and
characterized in the T-cell subset of the adaptive immune
system.81,82 Subsequently, a number of functions for PTPN2 in
the adaptive immune system have been described in the following
years. T cells express PTPN2 at especially high levels indicating
a speciﬁc role in this cell type.83 But also, B-cell development is
crucially regulated by PTPN2: The knockdown of PTPN2 leads,
besides other phenotypic changes in the respective animals, to an
early bone marrow B-cell deﬁciency, which is caused by a block of
the transition from pre-B cells to immature B cells.83 This is asso-
ciated with the secretion of high amounts of IFN-g, which in turn is
followed by phosphorylation of STAT molecules in the pre-B-cell
compartment.84 Normally, an important function of PTPN2 is to
dephosphorylate STAT1 leading to its inactivation.40 On ligand
binding, cytokine-receptor–associated kinases phosphorylate STAT
molecules, which subsequently dimerize and translocate to the
nucleus, where they act as transcription factors. PTPN2 counteracts
the activity of receptor-associated kinases by dephosphorylation of
STAT molecules, ultimately repressing cytokine signaling.41
Similar to the innate immune system, PTPN2 has an anti-
inﬂammatory role in the adaptive immune system, both in the T-
and B-cell compartment. Not surprisingly, mice homozygous
deﬁcient of PTPN2 suffer from uncontrolled inﬂammation and die
3 to 5 weeks after birth.61 They show severe alterations in organs
of the adaptive immune system including splenomegaly and
lymphadenopathy including impaired T- and B-cell functions.61
These data indicate an important role of PTPN2 in the adaptive
immune system and in the maturation of function of B and T cells
and subsequently in autoimmunity are supported by data from
human autoimmune diseases. In GWAS in patient cohorts with
different autoimmune diseases, SNPs of PTPN2 have been linked
with the development of the disease such as T1D and CD.70
Besides B- and T-cell maturation as well as STAT1 dephosphory-
lation, this may be caused by the important role of PTPN2 that has
as a key negative regulator of TCR signaling.70 PTPN2 dephos-
phorylates and inactivates Src family kinases to regulate T-cell
responses.70 By interfering with TCR signaling, PTPN2 attenuates
T-cell activation and proliferation and limits antigen-induced
responses. Controlled TCR activation and signaling is important
for the priming of cytotoxic CD8+ T cells to pathogens and path-
ologic antigens on one hand, as well as mediating peripheral toler-
ance to self-antigens or commensal microbes in the gut on the
other. PTPN2-deﬁcient antigen stimulated CD8+ T cells are no
longer self-tolerant and are able to destroy cells such as pancreatic
b cells in an autoreactive manner ﬁnally resulting in the develop-
ment of diabetes even in the absence of CD4+ T-helper cells.85
Thus, PTPN2 variants can redirect a normally tolerogenic CD8+
T-cell response into an autoreactive and destructive response.
In addition, a deﬁciency of PTPN2 was reported to enhance
naive T-cell responses to low-afﬁnity ligands.70 This may partially
be associated with the fact that STAT3 and STAT5 are further
substrates for dephosphorylation by PTPN2 (Fig. 5). Wiede et al70
reported that in the periphery PTPN2 deﬁciency resulted in
a memory phenotype of CD4+ T cells. In their mouse model
where PTPN2 lacks speciﬁcally in the T-cell compartment, the
number of T cells with an effector/memory phenotype increased
progressively from 4 to 12 weeks of age, which was paralleled by
a decrease in naive T-cell numbers. This may lead to a selection of
high-afﬁnity, potentially self-reactive T cells, which would repre-
sent another pathway of autoimmune disease induction by a lack
of PTPN2 function. In contrast, a lack of PTPN2 function does
not seems to inﬂuence the number of regulatory T cells and does
not interfere with regulatory T-cell function.
The increase in secretion of proinﬂammatory cytokines
found in other cell types certainly can also be found in T cells.
Misbalanced JAK and STAT signaling may play an important role
FIGURE 5. Signaling pathways regulated by PTPN2. PTPN2 dephosphorylates STAT1, STAT3, and STAT5 to reduce cytokine signaling. In addition,
loss of PTPN2 results in enhanced MAPK activation and decreased autophagy induction. In T cells, PTPN2 counteracts TCR-associated kinases and
thereby controls the reaction toward antigens maintaining tolerance toward self-antigens. Lck, lymphocyte tyrosine kinase; NOD2, nucleotide
oligomerization domain containing protein 2.
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here. An upregulation of IFN-g secretion, IL-12 secretion, and
other cytokines may play an important role for T-cell activation.83
Additionally, it has been demonstrated that PTPN2 is elevated in
naive T cells that leave the thymus. PTPN2-deﬁcient CD8+ T cells
undergo rapid lymphopenia-induced proliferation after transfer into
lymphopenic hosts acquiring characteristics of antigen-experienced
effector T cells. This increase in lymphopenia-induced proliferation
is associated with elevated TCR-dependent, but not IL-7-dependent
responses. This ﬁnally results in aberrant TCR function and the
development of autoimmunity86 (Fig. 6).
Despite the important role of PTPN2 and the ﬁnding of
relevant variants in autoimmune diseases such as CD and UC,
a detailed analysis of modiﬁcations of T-cell functions by those
variants or a complete lack of PTPN2 has not been performed yet.
Animal models may not be optimally suited as there are complex
interactions between the immune cells and also between adaptive
and innate immune mechanisms.
Role for Other PTPNs in
Intestinal Inﬂammation
In addition to PTPN2 and PTPN22, some other PTPNs
have also been associated with intestinal inﬂammation. In
particular, PTPN1 (PTP1B), PTPN6 (SHP-1), and PTPN11
(SHP-2) have already been demonstrated to play a role for the
development of intestinal inﬂammation.
PTP1B is a key molecule in modulating low-degree
inﬂammatory conditions such as diabetes. A recent study
demonstrated that PTP1B deﬁciency ameliorates DSS-induced
murine experimental colitis through expanding CD11b+Gr-1+
myeloid-derived suppressor cells. PTP1B null mice demonstrate
greater resistance to DSS-induced colitis, as reﬂected by slower
weight loss, greater survival rates, and decreased macrophage
inﬁltration into the colon. This resistance of PTP1B-deﬁcient mice
to DSS-induced colitis is based on the expansion of myeloid-
derived suppressor cells regulating cytokine secretion and activa-
tion of signaling molecules.87
A further study demonstrated a signiﬁcant association
between PTPN6 and UC in a collective of Tunisian patients with
IBD.88 On a functional level, PTPN6 has been identiﬁed as a crit-
ical regulator of Th17 development. Genetically or pharmacolog-
ically caused dysfunction of PTPN6 activity in T cells makes
these cells hyperresponsive to stimulation through IL-6 and
IL-21. Additionally, PTPN6 controls cytokine-induced phosphor-
ylation of STAT3 in primary CD4+ T-helper cells. These data
suggest a role for PTPN6 in the pathogenesis of IBD by modu-
lating Th17 cell development.89
FIGURE 6. The effect of loss of (functional) PTPN2 during intestinal inﬂammation. Loss of PTPN2 in experimental models or the presence of PTPN2
variants in humans results in several disease driving mechanisms ultimately maintaining intestinal disease. B, B cell; DC, dendritic cell; M, mac-
rophage; T, T cell.
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PTPN11 is a ubiquitously expressed cytoplasmic protein
tyrosine phosphatase. Genetic associations exist between UC, but
not CD, and PTPN11. The Hap 1 haplotype and its homozygous
Hap 1/Hap 1 diplotype of PTPN11 is signiﬁcantly increased in
patients with UC compared with control subjects.90 The expres-
sion of PTPN11 protein in the intestinal tissue of patients with UC
is reduced.91 On a functional level, it has been demonstrated that
pharmacologically induced interaction between PTPN11 and
cytosolic STAT1, what ﬁnally prevents the recruitment of STAT1
to the IFN-g receptor and inhibits STAT1 signaling, results in
reduced Th1 cytokine production and an improvement in 2,4,6-
trinitrobenzene sulfonic acid–induced colitis in mice. Inhibition of
PTPN11, vice versa, worsens colitis symptoms in vivo.92
Mice featuring an IEC-speciﬁc PTPN11 deletion feature
growth retardation and rapidly develop clinical and histological
signs of severe colitis. These animals also feature decreased
expression of claudins accompanied by enhanced intestinal
permeability and an upregulation of STAT3 and nuclear factor
kB activity as well as an induction of several epithelial chemo-
kines and cytokines. Interestingly, the development of colitis in
PTPN11 IEC speciﬁc knockout mice was remarkably impaired
by antibiotic treatment. A further study demonstrated that the
number of goblet cells in both the small intestine and colon of
theses mice is clearly reduced compared with control mice.
Furthermore, the PTPN11-deﬁcient mice showed marked
impairment of both, IEC migration along the crypt–villus axis
in the small intestine and development of intestinal organoids
from isolated crypts.91,93 These ﬁndings suggest that intestinal
epithelial PTPN11 might play a critical role for protecting the
intestinal epithelium and thereby for the prevention of gut
inﬂammation.
SUMMARY
PTPs play a crucial role for regulating intracellular
signaling events. Recent GWAS have associated a number of
PTPs with the onset of IBD. Evolving evidence emerges that
expression levels of PTPs, mainly PTPN2, PTPN22, and PTPN11
are altered in actively inﬂamed intestinal tissue. Furthermore, the
PTPs seem to be critical for protecting intestinal epithelial barrier
function, regulating innate and adaptive immune responses, and
ﬁnally for maintaining intestinal homeostasis. Dysfunction of
those PTPs results in aberrant and uncontrolled immune responses
that result in chronic inﬂammatory conditions. This way, it
becomes more and more evident that dysfunction of PTPs
displays an important factor in the pathogenesis of chronic
intestinal inﬂammation, in particular IBD.
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